HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maintenance ECT in intractable manic-depressive disorders.

Abstract
Twenty-two patients suffering from intractable recurrent unipolar or bipolar mood disorders were enrolled in a maintenance-ECT protocol (ECT-M) for more than 18 months, with a treatment at approximately monthly intervals. Eleven have continued treatment for > 2 years. Whereas 44% of the year had been spent in the hospital with at least three episodes a year prior to ECT-M, only 7% of the year was spent in the hospital during ECT-M with only one relapse every 16 months requiring admission (p < 0.001). Forty-five percent of the patients were in full remission and 27% in partial remission according to DSM-III-R criteria. ECT-M responsiveness of rapid-cyclers and delusional depressed patients usually drug refractory has been very encouraging with full or partial remission for 100% of rapid-cyclers and 80% of delusional depressed patients.
AuthorsJ M Vanelle, H Loo, A Galinowski, W de Carvalho, M C Bourdel, P Brochier, O Bouvet, T Brochier, J P Olie
JournalConvulsive therapy (Convuls Ther) Vol. 10 Issue 3 Pg. 195-205 (Sep 1994) ISSN: 0749-8055 [Print] United States
PMID7834256 (Publication Type: Journal Article)
Chemical References
  • Antidepressive Agents, Tricyclic
  • Carbamazepine
  • Lithium
Topics
  • Adult
  • Aged
  • Antidepressive Agents, Tricyclic (therapeutic use)
  • Bipolar Disorder (psychology, therapy)
  • Carbamazepine (therapeutic use)
  • Combined Modality Therapy
  • Delusions (psychology, therapy)
  • Depressive Disorder (psychology, therapy)
  • Electroconvulsive Therapy (methods)
  • Female
  • Follow-Up Studies
  • Humans
  • Lithium (therapeutic use)
  • Male
  • Middle Aged
  • Patient Readmission
  • Psychiatric Status Rating Scales
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: